Better
Treatments,
More Tomorrows

Better
Treatments,
More Tomorrows

We are
Advancing

A late-stage pipeline of product candidates for the treatment of hard-to-treat tumors and viruses.

Innovative
Therapies

Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).

Innovative
Therapies

Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).

AML Clinical Day Featuring Clinicians Martin S. Tallman, MD and Michael Andreeff, MD, PhD

May 7, 2024

Priority Development Pipeline

AML Patient Journey and the Annamycin Opportunity 

Latest Releases

Stock Information

NASDAQ: MBRX

NASDAQ: MBRX

Corporate

Presentation

Corporate

Presentation